## CYP3cide

Cat. No.:	HY-18642		
CAS No.:	1390637-82-7		
Molecular Formula:	$C_{26}H_{32}N_{8}$		
Molecular Weight:	456.59		
Target:	Cytochrome P450		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month

### SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (109.51 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1901 mL	10.9507 mL	21.9015 mL
	5 mM	0.4380 mL	2.1901 mL	4.3803 mL
	10 mM	0.2190 mL	1.0951 mL	2.1901 mL

Please refer to the solubility information to select the appropriate solvent.

<b>BIOLOGICAL ACT</b>	ΙVITY				
Description	CYP3cide (PF-4981517) is a potent, selective and time-dependent inhibitor of cytochrome P4503A4 (CYP3A4). The IC <sub>50</sub> values for Midazolam 1'-hydroxylase activity are 0.03 μM, 17 μM, and 71 μM for CYP3A4, CYP3A5, and CYP3A7, respectively. CYP3cide can be used to distinguish the contributions of CYP3A4 versus CYP3A5 on agent metabolism <sup>[1]</sup> .				
IC <sub>50</sub> & Target	CYP3A4 30 nM (EC50)	СҮРЗА5 17 µМ (ЕС50)	CYP3A7 71 μM (EC50)		
In Vitro	3800 ml • min <sup>-1</sup> • μmol <sup>-1</sup> is obs This observed efficiency equa to 1.6 min <sup>-1</sup> . When CYP3cide is genotyped polymorphic CYP3 abundance is significant <sup>[1]</sup> .	erved using human liver m ted to an apparent KI betwo s tested at a concentration A5 microsomes, the correla	an extreme metabolic inactivation efficiency (k <sup>inact</sup> /K <sup>I</sup> ) of 3300 to crosomes from donors of nonfunctioning CYP3A5 (CYP3A5 <sup>*</sup> 3/ <sup>*</sup> 3). een 420 and 480 nM with a maximal inactivation rate (kinact) equal and preincubation time to completely inhibit CYP3A4 in a library of tion of the remaining midazolam 1'-hydroxylase activity to CYP3A5 ese methods. They are for reference only.		

# Product Data Sheet

N-N



#### REFERENCES

[1]. Robert L Walsky, et al. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab Dispos. 2012 Sep;40(9):1686-97.

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA